Guidelines of treatment of patients with ANCA-associated vasculitis
- Autores: Bulanov N.M1, Tao E.A1, Novikov P.I1, Smirnova I.G1, Moiseev S.V1,2
-
Afiliações:
- I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
- M.V. Lomonosov Moscow State University
- Edição: Volume 7, Nº 6 (2021)
- Páginas: 72-80
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288413
- DOI: https://doi.org/10.18565/therapy.2021.6.72-80
- ID: 288413
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
N. Bulanov
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Email: nmbulanov@gmail.com
19021, Moscow, 11/5 Rossolimo Str. Tel.: +7 (499) 248-53-33
E. Tao
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Email: karovaikinaea@gmail.com
119021, Moscow, 11/5 Rossolimo Str. Tel.: +7 (499) 248-53-33
P. Novikov
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)119021, Moscow, 11/5 Rossolimo Str. Tel.: +7 (499) 248-53-33
I. Smirnova
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Email: mailbox.smirnova@gmail.com
119021, Moscow, 11/5 Rossolimo Str. Tel.: +7 (499) 248-53-33
S. Moiseev
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University); M.V. Lomonosov Moscow State University
Email: avt420034@gmail.com
119021, Moscow, 11/5 Rossolimo Str. Tel.: +7 (499) 248-53-33
Bibliografia
- Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1): 1-11. doi: 10.1002/art.37715.
- Lyons P.A., Rayner T., Trivedi S. et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012; 367(3): 214-23. doi: 10.1056/NEJMoa1 108735.
- Xie G., Roshandel D., Sherva R. et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: Evidence from genome-wide analysis. Arthritis Rheum. 2013; 65(9): 2457-68. doi: 10.1002/art.38036.
- Tadema H., Abdulahad W., Lepse N. et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford). 2011; 50(4): 689-96. doi: 10.1093/rheumatology/keq375.
- Gomez-Puerta J.A., Gedmintas L., Costenbader K.H. The association between silica exposure and development of ANCA-associated vasculitis: Systematic review and meta-analysis. Autoimmun Rev. 2013; 12(12): 1129-35. doi: 10.1016/j. autrev.2013.06.016.
- Rozina T., Fastovets S., Lee 0. et al. D-penicillamine-induced autoimmune disorders. Dig Liver Dis. 2019; 51(12): 1741-42. doi: 10.1016/j.dld.2019.08.025.
- Watts R.A., Mahr A., Mohammad A.J. et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015; 30 Suppl 1: i14-22. doi: 10.1093/ndt/gfv022.
- de Lind van Wijngaarden R.A.F., Robert A., Hauer H. et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006; 17(8): 2264-74. doi: 10.1681/ASN.2005080870.
- Томилина Н.А., Бирюкова Л.С., Фролова Н.Ф. с соавт. Клинико-морфологическая характеристика и прогноз разных гистоморфологических вариантов быстропрогрессирующего гломерулонефрита, ассоциированного с АНЦА-васкулитом. Нефрология и диализ. 2017; 4: 466-477. @@ Tomilina N.A., Biryukova L.S., Frolova N.D. et al. Clinical and morphological characteristics and prognosis of different histomorphological variants of rapidly progressing glomerulonephritis associated with ANCA-vasculitis. Nefrologiya i dializ = Nephrology and Dialysis. 2017; 4: 466-477 (In Russ.).
- Буланов Н.М., Моисеев С.В., Новиков П.И. с соавт. Поражение почек при различных вариантах АНЦА-ассоциированных васкулитов. Клиническая фармакология и терапия. 2016; 5: 23-29. @@ Bulanov N.M., Moiseev S.V., Novikov P.I. et al. Kidney damage in different variants of ANCA-associated vasculitis. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2016; 5: 23-29 (In Russ.).
- Yates M., Watts R.A., Bajema I.M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016; 75(9): 1583-94. doi: 10.1136/annrheumdis-2016-209133.
- Novack S.N., Pearson C.M. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med. 1971; 284(17): 938-42. doi: 10.1056/NEJM197104292841703.
- Faurschou M., Sorensen I., Mellemkjaer L. et al. Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008; 35(1): 100-05.
- Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med. 1992; 116(6): 488-98. doi: 10.7326/0003-4819-116-6-488.
- de Groot K., Harper L., Jayne D. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2009; 150(10): 670-80. doi: 10.7326/0003-4819-150-10-200905190-00004.
- Harper L., Morgan M., Walsh M. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis. 2012; 71(6): 955-60. doi: 10.1136/annrheumdis-2011-200477.
- Stone J.H., Merkel P., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3): 221-32. doi: 10.1056/NEJMoa0909905.
- Jones R.B., Tervaert J.W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010; 363(3): 211-20. doi: 10.1056/NEJMoa0909169.
- Klemmer P.J., Chalermskulrat W., Reif M.S. et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003; 42(6): 1149-53. doi: 10.1053/j.ajkd.2003.08.015.
- Szpirt W.M., Heaf J.G., Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. Nephrol Dial Transplant. 2011; 26(1): 206-13. doi: 10.1093/ ndt/gfq360.
- Jayne D.R.W., Gaskin G., Rasmussen N. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18(7): 2180-88. doi: 10.1681/ASN.2007010090.
- Walsh M., Casian A., Flossmann 0. et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013; 84(2): 397-402. doi: 10.1038/ ki.2013.131.
- Walsh M., Merkel P., Peh C. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020; 382(7): 622-31. doi: 10.1056/NEJMoa1803537.
- De Groot K., Rasmussen N., Bacon P. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52(8): 2461-69. doi: 10.1002/art.21142.
- Faurschou M., Westman K., Rasmussen N. et al. Brief report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012; 64(10): 3472-77. doi: 10.1002/art.34547.
- Tuin J., Stassen P., Bogdan D. et al. Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2019; 14(7): 1021-28. doi: 10.2215/CJN.11801018.
- Jones R.B., Hiemstra T., Ballarin J. et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis. 2019; 78(3): 399-405. doi: 10.1136/ annrheumdis-2018-214245.
- Unizony S., Villarreal M., Miloslavsky E. et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann. Rheum. Dis. 2016; 75(6): 1166-69. doi: 10.1136/ annrheumdis-2015-208073.
- Miloslavsky E.M., Specks U., Merkel P. et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol. 2015; 67(6): 1629-36. doi: 10.1002/art.39104
- Hellmich B., Flossmann O., Gross W. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5): 605-17. doi: 10.1136/ard.2006.062711
- Miloslavsky E.M., Specks U., Merkel P. et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013; 65(9): 2441-49. doi: 10.1002/art.38044.
- Pullerits R., Ljevak M., Vikgren J. et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre. Scand J Immunol. 2012; 76(4): 411-20. doi: 10.1111/j.1365-3083.2012.02747.x.
- Seror R., Pagnoux C., Ruivard M. et al. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010; 69(12): 2125-30. doi: 10.1136/ard.2010.131953.
- Talar-Williams C., Hijazi Y., Walther M. et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996; 124(5): 477. doi: 10.7326/0003-4819-124-5-199603010-00003.
- Knight A., Askling J., Granath F. et al. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004 ;63(10): 1307-11. doi: 10.1136/ard.2003.019125.
- Jayne D., Rasmussen N., Andrassy K. et al. A Randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349(1): 36-44. doi: 10.1056/NEJMoa020286.
- Anstey A., Lennard L., Mayou S. et al. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: A review. J R Soc Med. 1992; 85(12): 752-56.
- Guillevin L., Pagnoux C., Karras A. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014; 371(19): 1771-80. doi: 10.1056/NEJMoa1404231.
- Smith R., Jayne D., Merkel P. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease - ACR meeting abstracts. Arthritis Rheumatol. 2019; 71(supl 10).
- Charles P., Terrier B., Perrodeau E. et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018; 77(8): 1143-49. doi: 10.1136/annrheumdis-2017-212878.
- Hiemstra T.F., Walsh M., Mahr A. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis. JAMA. 2010; 304(21): 2381. doi: 10.1001/jama.2010.1658.
- Langford C.A., Talar-Williams C., Barron K. et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003; 114(6): 463-69. doi: 10.1016/s0002-9343(03)00077-9.
- Puechal X., Pagnoux C., Rerrodeau E. et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Arthritis Rheumatol. 2016; 68(3): 690-701. doi: 10.1002/art.39450.
- Springer J., Nutter B., Langford C. et al. Granulomatosis with polyangiitis (Wegener's): Impact of maintenance therapy duration. Medicine (Baltimore). 2014; 93(2): 82-90. doi: 10.1097/MD.0000000000000020.
- Karras A., Pagnoux C., Haubitz M. et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017; 76(10): 1662-68. doi: 10.1136/annrheumdis-2017-211123.
- Charles P., Perrodeau E., Samson M. et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2020; 173(3): 179-87. doi: 10.7326/M19-3827.
- Walsh M., Merkel P., Mahr A. et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken). 2010; 62(8): 1166-73. doi: 10.1002/acr. 20176.
- Pagnoux C., Quemeneur T., Ninet J. et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015; 67(4): 1117-27. doi: 10.1002/art.39011.
- Mahr A., Girard T., Agher R. et al. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology (Oxford). 2001; 40(5): 492-98. doi: 10.1093/rheumatology/40.5.492.
- Jeffs L.S., Peh C., Jase M. et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 2015; 20(5): 343-51. doi: 10.1111/nep.12416
- Stassen P.M., Sanders J., Kallenberg C. et al. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2007; 23(2): 654-58. doi: 10.1093/ndt/gfm640
- Rondaan C., Furer V., Heijstek M. et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5(2): e001035. doi: 10.1136/rmdopen-2019-001035.
- Lee J.J., Pope J.E. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014; 16(5): 435. doi: 10.1186/s13075-014-0435-y.
- Yamada Y., Harada M., Hara Y. et al. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis. Arthritis Res Ther. 2021; 23(1): 28. doi: 10.1186/s13075-021-02415-z.
- Smith R., Jones R., Specks U. et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020; 79(9): 1243-49. doi: 10.1136/annrheumdis-2019-216863